The paper is under review in the Proceedings of ICCS-2021, Springer, 2021

Pathology dynamics in healthy-toxic protein interaction and the multiscale analysis of neurodegenerative diseases^{*}

Swadesh Pal¹[0000–0002–6873–7338] and Roderick Melnik^{1,2}[0000–0002–1560–6684]

¹ MS2Discovery Interdisciplinary Research Institute, Wilfrid Laurier University,
Waterloo, Canada

² BCAM- Basque Center for Applied Mathematics, Bilbao, Spain
rmelnik@wlu.ca

Abstract. Neurodegenerative diseases are frequently associated with aggregation and propagation of toxic proteins. In particular, it is well known that along with amyloid-beta, the tau protein is also driving Alzheimer’s disease. Multiscale reaction-diffusion models can assist in our better understanding of the evolution of the disease. We have modified the heterodimer model in such a way that it can now capture some of critical characteristics of this evolution such as the conversion time from healthy to toxic proteins. We have analyzed the modified model theoretically and validated the theoretical findings with numerical simulations.

Keywords: Alzheimer’s disease · coupled multiscale models · amyloid-beta and tau proteins · neurodegenerative disorders · Holling type-II.

1 Introduction

Alzheimer’s disease (AD) is an example of a neurodegenerative disease, associated with aggregation and propagation of toxic proteins [1]. Initially, the “amyloid cascade hypothesis” has dominated for the treatments [2, 3]. However, due to the failures of large clinical trials, researchers started focussing on some other mechanisms. It is now well accepted that the tau-protein (τP) is a viable alternative to the “amyloid cascade hypothesis”.

The τP plays a prominent role as a secondary agent in the disease development. For example, (i) frontotemporal lobar degeneration is mostly dominated by τP spreading [4], (ii) neurofibrillary tangles (NFT) are correlated in brain atrophy in AD [5, 6], (iii) lower τP concentration prevents neuronal loss [7], (iv) τP also reduces neural activity [8], etc. This helps to explain the relative

^{*} Authors are grateful to the NSERC and the CRC Program for their support. RM is also acknowledging support of the BERC 2018-2021 program and Spanish Ministry of Science, Innovation and Universities through the Agencia Estatal de Investigación (AEI) BCAM Severo Ochoa excellence accreditation SEV-2017-0718 and the Basque Government fund AI in BCAM EXP. 2019/00432.

lack of clinical improvements. There is an open debate in the literature on the roles of $A\beta$ proteopathy and τP tauopathy in AD but it is clear by now that “the amyloid – β – τ nexus is central to disease-specific diagnosis, prevention and treatment” [9]. In recent years, many researchers have focussed on $A\beta$ and τP interaction. Moreover, in neurodegenerative diseases, the protein-protein interactions become a key for understanding both spreading and toxicity of the proteins [10–13]. There are some crucial observations specific to AD [10, 14]: (i) the seeding of new toxic τP is enhanced by the presence of $A\beta$, (ii) the toxicity of $A\beta$ depends on the presence of τP , and (iii) $A\beta$ and τP amplify each other’s toxic effects.

Mathematical models are widely used for the interpretation of biological processes, and this field is not an exception. Building on earlier advances [15–20], we analyze AD by a deterministic mathematical modelling approach and predict the dynamics of the disease based on several novel features of our model. Recall that the heterodimer model describes the interaction between the healthy and toxic proteins [21–25]. In the heterodimer model, with an increase in the healthy protein density, the toxic protein conversion increases. We have modified that linear conversion term to include nonlinear effects via Holling type-II functional response. In this case, the toxic protein’s conversion rate remains constant with an increase in the healthy protein density. This modification incorporates the reaction time (conversion from healthy protein to toxic protein). We have considered two modified coupled heterodimer systems for healthy-toxic interactions for both proteins, $A\beta$ and τP , along with a single balance interaction term. This study identifies two types of disease propagation modes depending on the parameters: primary tauopathy and secondary tauopathy.

This manuscript is organized as follows. In Section 2, we briefly discuss the heterodimer model and its modification. Temporal behaviour of the modified model is analyzed in Section 3, focussing on possible stationary points and linear stability. In Section 4, we provide results on the wave propagation described by a simplified model, specific to stationary states. Section 5 is devoted to a detailed analysis of the AD propagation in terms of primary and secondary tauopathies. Concluding remarks are given in Section 6.

2 Mathematical Model

We first consider the usual heterodimer model for the healthy and toxic variants of the proteins $A\beta$ and τP . Let Ω be a spatial domain in $\mathbb{R}^3$. For $\mathbf{x} \in \Omega$ and time $t \in \mathbb{R}^+$, let $u = u(\mathbf{x}, t)$ and $\tilde{u} = \tilde{u}(\mathbf{x}, t)$ be healthy and toxic concentrations of the protein $A\beta$, respectively. Similarly, we denote $v = v(\mathbf{x}, t)$ and $\tilde{v} = \tilde{v}(\mathbf{x}, t)$ the healthy and toxic concentrations of τP , respectively. The concentration evolution is then given by the following system of coupled partial differential equations [14,

22]:

$$\frac{\partial u}{\partial t} = \nabla \cdot (\mathbf{D}_1 \nabla u) + a_0 - a_1 u - a_2 u \tilde{u}, \quad (1a)$$

$$\frac{\partial \tilde{u}}{\partial t} = \nabla \cdot (\tilde{\mathbf{D}}_1 \nabla \tilde{u}) - \tilde{a}_1 \tilde{u} + a_2 u \tilde{u}, \quad (1b)$$

$$\frac{\partial v}{\partial t} = \nabla \cdot (\mathbf{D}_2 \nabla v) + b_0 - b_1 v - b_2 v \tilde{v} - b_3 \tilde{u} v \tilde{v}, \quad (1c)$$

$$\frac{\partial \tilde{v}}{\partial t} = \nabla \cdot (\tilde{\mathbf{D}}_2 \nabla \tilde{v}) - \tilde{b}_1 \tilde{v} + b_2 v \tilde{v} + b_3 \tilde{u} v \tilde{v}. \quad (1d)$$

In system (1), a_0 and b_0 are the mean production rates of healthy proteins, $a_1, b_1, \tilde{a}_1$ and $\tilde{b}_1$ are the mean clearance rates of healthy and toxic proteins, and a_2 and b_2 represent the mean conversion rates of healthy proteins to toxic proteins. The parameter b_3 is the coupling constant between the two proteins $A\beta$ and τP . Further, $\mathbf{D}_1, \tilde{\mathbf{D}}_1, \mathbf{D}_2$ and $\tilde{\mathbf{D}}_2$ are the diffusion tensors which characterize the spreading of each proteins. We assume that all variables and initial conditions are non-negative and also all the parameters to be strictly positive.

Here, the healthy protein is approached by the toxic protein, and after transitions, a healthy protein is converted into a toxic state. In the current formulation, we have assumed that the probability of a given toxic protein encountering healthy protein in a fixed time interval T_t , within a fixed spatial region, depends linearly on the healthy protein density. In this case, the total density of the healthy proteins u converted by the toxic proteins $\tilde{u}$ can be expressed as $\tilde{u} = aT_s u$, following the Holling functional response idea [26]. The parameter T_s is the time to getting contact with each other and a is a proportionality constant. If there is no reaction time, then $T_s = T_t$ and hence we get a linear conversion rate $\tilde{u} = aT_t u$. Now, if each toxic protein requires a reaction time h for healthy proteins that are converted, then the time available to getting contact becomes $T_s = T_t - h\tilde{u}$. Therefore, $\tilde{u} = a(T_t - h\tilde{u})u$, hence $\tilde{u} = aT_t u / (1 + ah\tilde{u})$, which is a nonlinear conversion rate. So, we modify the above model (1) as follows:

$$\frac{\partial u}{\partial t} = \nabla \cdot (\mathbf{D}_1 \nabla u) + a_0 - a_1 u - \frac{a_2 u}{1 + e_1 u} \tilde{u}, \quad (2a)$$

$$\frac{\partial \tilde{u}}{\partial t} = \nabla \cdot (\tilde{\mathbf{D}}_1 \nabla \tilde{u}) - \tilde{a}_1 \tilde{u} + \frac{a_2 u}{1 + e_1 u} \tilde{u}, \quad (2b)$$

$$\frac{\partial v}{\partial t} = \nabla \cdot (\mathbf{D}_2 \nabla v) + b_0 - b_1 v - \frac{b_2 v}{1 + e_2 v} \tilde{v} - b_3 \tilde{u} v \tilde{v}, \quad (2c)$$

$$\frac{\partial \tilde{v}}{\partial t} = \nabla \cdot (\tilde{\mathbf{D}}_2 \nabla \tilde{v}) - \tilde{b}_1 \tilde{v} + \frac{b_2 v}{1 + e_2 v} \tilde{v} + b_3 \tilde{u} v \tilde{v}, \quad (2d)$$

where $e_1 (= a_\beta h_\beta)$ and $e_2 (= a_\tau h_\tau)$ are dimensionless parameters. We use no-flux boundary conditions and non-negative initial conditions. Here, in model (2), the rate of conversion of the healthy protein by the toxic protein increases as the healthy protein density increases, but eventually it saturates at the level where the rate of conversion remains constant regardless of increases in healthy protein

density. On the other hand, in model (1), the rate of conversion of the healthy protein by the toxic protein rises constantly with an increase in the healthy protein density.

3 Temporal Dynamics

For studying the wave propagation based on the reaction-diffusion model (2), we will first find homogeneous steady-states of the system. The homogeneous steady-states of the system (2) can be determined by finding the equilibrium points of the following system

$$\frac{du}{dt} = a_0 - a_1u - \frac{a_2u}{1 + e_1u}\tilde{u}, \quad (3a)$$

$$\frac{d\tilde{u}}{dt} = -\tilde{a}_1\tilde{u} + \frac{a_2u}{1 + e_1u}\tilde{u}, \quad (3b)$$

$$\frac{dv}{dt} = b_0 - b_1v - \frac{b_2v}{1 + e_2v}\tilde{v} - b_3\tilde{u}v\tilde{v}, \quad (3c)$$

$$\frac{d\tilde{v}}{dt} = -\tilde{b}_1\tilde{v} + \frac{b_2v}{1 + e_2v}\tilde{v} + b_3\tilde{u}v\tilde{v}, \quad (3d)$$

with non-negative initial conditions.

3.1 Stationary Points

The system (3) always has a disease-free state called a healthy stationary state. Depending on the parameter values, the system may possess more stationary points. We summarise each possible stationary state in the following:

1. Healthy $A\beta$ - healthy τP : It is the trivial stationary state and is given by

$$(u_1, \tilde{u}_1, v_1, \tilde{v}_1) = \left(\frac{a_0}{a_1}, 0, \frac{b_0}{b_1}, 0 \right). \quad (4)$$

This stationary state is the same for both systems, (1) and (2), due to zero toxic loads.

2. Healthy $A\beta$ - toxic τP : The stationary state of “healthy $A\beta$ - toxic τP ” is given by

$$(u_2, \tilde{u}_2, v_2, \tilde{v}_2) = \left(\frac{a_0}{a_1}, 0, \frac{\tilde{b}_1}{b_2 - e_2\tilde{b}_1}, \frac{b_0(b_2 - e_2\tilde{b}_1) - b_1\tilde{b}_1}{\tilde{b}_1(b_2 - e_2\tilde{b}_1)} \right). \quad (5)$$

For the non-negativity of the stationary point (5), we must have $b_2 > e_2\tilde{b}_1$ and $b_0/b_1 \geq \tilde{b}_1/(b_2 - e_2\tilde{b}_1)$.

3. Toxic $A\beta$ - healthy τP : The stationary state of “toxic $A\beta$ - healthy τP ” is given by

$$(u_3, \tilde{u}_3, v_3, \tilde{v}_3) = \left(\frac{\tilde{a}_1}{a_2 - e_1 \tilde{a}_1}, \frac{a_0(a_2 - e_1 \tilde{a}_1) - a_1 \tilde{a}_1}{\tilde{a}_1(a_2 - e_1 \tilde{a}_1)}, \frac{b_0}{b_1}, 0 \right). \quad (6)$$

For the non-negativity of the stationary point (6), we must have $a_2 > e_1 \tilde{a}_1$ and $a_0/a_1 \geq \tilde{a}_1/(a_2 - e_1 \tilde{a}_1)$.

4. Toxic $A\beta$ - toxic τP : Suppose $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$ is a stationary state of the “toxic $A\beta$ - toxic τP ” type. In this case, we obtain $u_4 = u_3$, $\tilde{u}_4 = \tilde{u}_3$, $\tilde{v}_4 = (b_0 - b_1 v_4)/b_1$ and v_4 satisfy the quadratic equation

$$b_3 e_2 \tilde{u}_4 v_4^2 + (b_3 \tilde{u}_4 - e_2 \tilde{b}_1 + b_2) v_4 - \tilde{b}_1 = 0. \quad (7)$$

The equation (7) always has a real positive solution. For the uniqueness of v_4 , we must have $b_3 \tilde{u}_4 - e_2 \tilde{b}_1 + b_2 \geq 0$. Also, for the positivity of $\tilde{v}_4$, we need $v_4 < b_0/b_1$.

Note that under small perturbations of any one of these stationary points, the trajectories may or may not come to that stationary point. Next, we examine this situation in more detail by the linear stability analysis.

3.2 Linear Stability Analysis

For the stability analysis, we linearize the system (3) about any of the stationary points $(u_*, \tilde{u}_*, v_*, \tilde{v}_*)$. The coefficient matrix $\mathbf{M}$ of the resulting system is the Jacobian matrix of the system (3) and is given by

$$\begin{bmatrix} -a_1 - \frac{a_2 \tilde{u}_*}{(1+e_1 u_*)^2} & -\frac{a_2 u_*}{1+e_1 u_*} & 0 & 0 \\ \frac{a_2 \tilde{u}_*}{(1+e_1 u_*)^2} & \frac{a_2 u_*}{1+e_1 u_*} - \tilde{a}_1 & 0 & 0 \\ 0 & -b_3 v_* \tilde{v}_* & -b_1 - \frac{b_2 \tilde{v}_*}{(1+e_2 v_*)^2} - b_3 \tilde{u}_* \tilde{v}_* & -\frac{b_2 v_*}{1+e_2 v_*} - b_3 \tilde{u}_* v_* \\ 0 & b_3 v_* \tilde{v}_* & \frac{b_2 \tilde{v}_*}{(1+e_2 v_*)^2} + b_3 \tilde{u}_* \tilde{v}_* & \frac{b_2 v_*}{1+e_2 v_*} + b_3 \tilde{u}_* v_* - \tilde{b}_1 \end{bmatrix}. \quad (8)$$

Now, the eigenvalues of the Jacobian matrix $\mathbf{M}$ are given by

$$\begin{aligned} \lambda_1 &= -\frac{1}{2}(B + \sqrt{B^2 - 4C}), \lambda_2 = -\frac{1}{2}(B - \sqrt{B^2 - 4C}), \\ \lambda_3 &= -\frac{1}{2}(\hat{B} + \sqrt{\hat{B}^2 - 4\hat{C}}), \lambda_4 = -\frac{1}{2}(\hat{B} - \sqrt{\hat{B}^2 - 4\hat{C}}), \end{aligned}$$

where $B = a_1 + \tilde{a}_1 + a_2 \tilde{u}_*/(1+e_1 u_*)^2 - a_2 u_*/(1+e_1 u_*)$, $C = a_1 \tilde{a}_1 + \tilde{a}_1 a_2 \tilde{u}_*/(1+e_1 u_*)^2 - a_1 a_2 u_*/(1+e_1 u_*)$, $\hat{B} = b_1 + \tilde{b}_1 + b_3 \tilde{u}_* (\tilde{v}_* - v_*) + b_2 \tilde{v}_*/(1+e_2 v_*)^2 - b_2 v_*/(1+e_2 v_*)$ and $\hat{C} = b_1 \tilde{b}_1 + b_3 \tilde{u}_* (\tilde{b}_1 \tilde{v}_* - b_1 v_*) + \tilde{b}_1 b_2 \tilde{v}_*/(1+e_2 v_*)^2 - b_1 b_2 v_*/(1+e_2 v_*)$.

For each of the stationary points, we find the Jacobian matrix $\mathbf{M}$ and all its eigenvalues $\lambda_i, i = 1, 2, 3, 4$. Hence, the conclusion can be drawn easily, because for a given stationary point, if all the eigenvalues have negative real parts, this stationary point is stable, otherwise it is unstable.

4 Wave Propagation

We analyze travelling wave solutions of the spatio-temporal model (2) in one dimension ($\Omega = \mathbb{R}$) connecting any two stationary states $(u_i, \tilde{u}_i, v_i, \tilde{v}_i)$, $i = 1, 2, 3, 4$ [21]. First, we consider the travelling wave emanating from healthy stationary state $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ and connecting to $(u_2, \tilde{u}_2, v_2, \tilde{v}_2)$. For analysing the travelling wave fronts, we linearize the spatio-temporal model (2) around the healthy stationary state which leads to the following uncoupled system

$$\frac{\partial \tilde{u}}{\partial t} = \tilde{d}_1 \frac{\partial^2 \tilde{u}}{\partial x^2} + \frac{a_2 u_1}{1 + e_1 u_1} - \tilde{a}_1, \quad (9a)$$

$$\frac{\partial \tilde{v}}{\partial t} = \tilde{d}_2 \frac{\partial^2 \tilde{v}}{\partial x^2} + \frac{b_2 v_1}{1 + e_2 v_1} - \tilde{b}_1. \quad (9b)$$

Firstly, for the travelling wave solution, we substitute $\tilde{u}(x, t) = \tilde{u}(x - ct) \equiv \tilde{u}(z)$, $\tilde{v}(x, t) = \tilde{v}(x - ct) \equiv \tilde{v}(z)$ in (9) and will look for linear solutions of the form $\tilde{u} = C_1 \exp(\lambda z)$, $\tilde{v} = C_2 \exp(\lambda z)$. Then, the minimum wave speeds $c_{\min}$ are given by

$$c_{\beta}^{(12)} = 0 \text{ and } c_{\tau}^{(12)} = 2\sqrt{\tilde{d}_2 \left(\frac{b_2 v_1}{1 + e_2 v_1} - \tilde{b}_1 \right)}. \quad (10)$$

Here, $c_{\beta}^{(ij)}$ and $c_{\tau}^{(ij)}$ denote the speeds of the front from state i to the state j for the $A\beta$ fields $(u, \tilde{u})$ and τP fields $(v, \tilde{v})$, respectively.

Similarly, the minimum wave speeds for the travelling wave fronts emanating from healthy stationary state $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ and connecting to $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ are given by

$$c_{\beta}^{(13)} = 2\sqrt{\tilde{d}_1 \left(\frac{a_2 u_1}{1 + e_1 u_1} - \tilde{a}_1 \right)} \text{ and } c_{\tau}^{(13)} = 0. \quad (11)$$

Also, we have

$$c_{\beta}^{(14)} = c_{\beta}^{(13)} \text{ and } c_{\tau}^{(14)} = c_{\tau}^{(12)}. \quad (12)$$

Secondly, we consider the travelling wave emanating from the stationary state $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ and connecting to $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$. We linearize the spatio-temporal model (2) around $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ and repeat the same techniques to deduce that

$$c_{\beta}^{(34)} = 0 \text{ and } c_{\tau}^{(34)} = 2\sqrt{\tilde{d}_2 \left(\frac{b_2 v_3}{1 + e_2 v_3} + b_3 \tilde{u}_3 v_3 - \tilde{b}_1 \right)}. \quad (13)$$

5 Results and Discussion

A “healthy $A\beta$ - healthy τP ” stationary state satisfies $\tilde{u} = \tilde{v} = 0$. The non-existence of a physically relevant healthy state occurs due to a failure of healthy

clearance, which is either with an $A\beta$ clearance or with a τP clearance. To start with, we consider the following balance of clearance inequalities:

$$\frac{a_0}{a_1} < \frac{\tilde{a}_1}{a_2 - e_1 \tilde{a}_1}, \quad \frac{b_0}{b_1} < \frac{\tilde{b}_1}{b_2 - e_2 \tilde{b}_1}. \quad (14)$$

Now, if (14) holds for the stationary point $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ in (4), then all the eigenvalues corresponding to the Jacobian matrix $\mathbf{M}$ have negative real parts. So, given the small amounts of the production of toxic $A\beta$ or toxic τP , or excess amounts of the production of healthy $A\beta$ or healthy τP , the system would be approaching towards the “healthy $A\beta$ - healthy τP ” stationary state.

Due to the failure of the clearance inequality (14), a transcritical bifurcation occurs for the homogeneous system (3). Hence, all the other stationary states $(u_i, \tilde{u}_i, v_i, \tilde{v}_i)$, $i = 2, 3, 4$ are physically meaningful and a pathological development becomes possible. Motivated by [14], we fix the parameter values as $a_0 = a_1 = a_2 = b_0 = b_1 = b_2 = 1$ and $e_1 = e_2 = 0.1$. Now, we fix $\tilde{a}_1 = 3/4$, $\tilde{b}_1 = 4/3$ and we take b_3 as the bifurcation parameter. For $b_3 < 1.575$, the system has only two stationary points $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ and $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$. The equilibrium point $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ is saddle and $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ is stable. A non-trivial stationary point $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$ is generated through a transcritical bifurcation at $b_3 = 1.575$. Then $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ changes its stability to $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$ and becomes saddle (see Fig. 1).

Fig. 1: Transcritical bifurcation diagram of the stationary points for the system (3). (Parameter values: $a_0 = a_1 = a_2 = b_0 = b_1 = b_2 = 1$, $\tilde{a}_1 = 3/4$, $\tilde{b}_1 = 4/3$, $e_1 = e_2 = 0.1$.)

These results could lead to a number of important observations. For example, due to the instability of the healthy stationary state of the system (3), a pro-

teopathic brain patient would be progressing toward a disease state. The actual state would depend on the parameter values. If $b_0/b_1 \geq \tilde{b}_1/(b_2 - e_2\tilde{b}_1)$ holds, then $(u_2, \tilde{u}_2, v_2, \tilde{v}_2)$ exists and if $a_0/a_1 \geq \tilde{a}_1/(a_2 - e_1\tilde{a}_1)$ holds, then $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ exists. Sometimes both the relations hold simultaneously. Also, the proteopathic state $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$ exists if $b_0/b_1 > v_4$ holds. Since, $\tilde{u}_4 = \tilde{u}_3$, we can choose b_3 in such a way that $b_3\tilde{u}_4 - e_2\tilde{b}_1 + b_2 \geq 0$. Therefore, to produce tau proteopathy, the stationary state $(u_2, \tilde{u}_2, v_2, \tilde{v}_2)$ is not needed. So, we study only two types of patient proteopathies: (i) primary tauopathy and (ii) secondary tauopathy.

For the primary tauopathy, which is usually related to neurodegenerative diseases such as AD, all the four stationary states exist i.e., both the conditions $b_0/b_1 \geq \tilde{b}_1/(b_2 - e_2\tilde{b}_1)$ and $a_0/a_1 \geq \tilde{a}_1/(a_2 - e_1\tilde{a}_1)$ hold. In this case, we have plotted the dynamics of the system (3) in Fig. 2(a). Also, for the secondary tauopathy, only three stationary states exist. Here, the inequality $a_0/a_1 \geq \tilde{a}_1/(a_2 - e_1\tilde{a}_1)$ is true and the other inequality fails. An example of secondary tauopathy is shown in Fig. 2(b). Comparing the homogeneous systems corresponding to (1) and (2), the modified system requires less toxic load.

Fig. 2: Phase plane $(\tilde{u}, \tilde{v})$ with four and three stationary points for the system (3): (a) $\tilde{b}_1 = 3/4, b_3 = 0.5$ and (b) $\tilde{b}_1 = 4/3, b_3 = 3$. (Parameter values: $a_0 = a_1 = a_2 = b_0 = b_1 = b_2 = 1, \tilde{a}_1 = 3/4, e_1 = e_2 = 0.1$.)

For the wave propagation, we consider the spatial domain in one dimension $[-100, 100]$ as an example. However, the results are robust for a wide range of intervals. We take the initial condition $(u(x, 0), \tilde{u}(x, 0), v(x, 0), \tilde{v}(x, 0))$ for the primary tauopathy as $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ for $-100 \leq x \leq -95$, $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ for $-95 < x < 95$ and $(u_2, \tilde{u}_2, v_2, \tilde{v}_2)$ for $95 \leq x \leq 100$. On the other hand, the initial condition $(u(x, 0), \tilde{u}(x, 0), v(x, 0), \tilde{v}(x, 0))$ for the secondary tauopathy has been taken as $(u_3, \tilde{u}_3, v_3, \tilde{v}_3)$ for $-100 \leq x \leq -95$, $(u_1, \tilde{u}_1, v_1, \tilde{v}_1)$ for $-95 < x < 95$ and $(u_2, \tilde{u}_2, v_2, 10^{-6})$ for $95 \leq x \leq 100$.

We have shown the wave propagation for the primary tauopathy in Fig. 3 at different time steps $t = 50, 150, 180$ and 220 . Motivated by Thompson et al., we have chosen the parameter values as $a_0 = a_1 = a_2 = b_0 = b_1 = b_2 = 1, \tilde{a}_1 = \tilde{b}_1 = 3/4, b_3 = 0.5, e_1 = e_2 = 0.1, d_1 = \tilde{d}_1 = d_2 = \tilde{d}_2 = 1$ and no-flux

boundary conditions for all the variables. For these parametric values, we obtain $c_\beta^{(14)} = c_\tau^{(12)} = c_\tau^{(14)} = 0.798$ and $c_\tau^{(34)} = 1.068$. In the simulation, we have considered the toxic $A\beta$ front on the left side of the domain and toxic τP on the right. Initially, the toxic $A\beta$ front propagates to the right with speed $c_\beta^{(14)}$ and toxic τP propagates to the left with speed $c_\tau^{(12)}$. After overlapping both the fronts, τP increases its concentration and connects to $\tilde{v}_4$. Then, the left front of the wave of τP boosts its speed to $c_\tau^{(34)}$ and moves to the left. On the other hand, the right front of the wave of τP moves with speed $c_\tau^{(14)}$, it eventually fills the domain and the entire system converges to the stable equilibrium solution $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$.

Fig. 3: Front propagations of $\tilde{u}$ and $\tilde{v}$ for the system (2) at different time steps: (a) $t = 50$, (b) $t = 150$, (c) $t = 180$ and (d) $t = 220$.

In Fig. 4, we plot wave propagation for the secondary tauopathy at different time steps $t = 60, 250, 400$ and 425 . We have chosen the parameter values as $a_0 = a_1 = a_2 = b_0 = b_1 = b_2 = 1, \tilde{a}_1 = 3/4, \tilde{b}_1 = 4/3, b_3 = 3, e_1 = e_2 = 0.1, d_1 = \tilde{d}_1 = d_2 = \tilde{d}_2 = 1$ and no-flux boundary conditions for all the variables. For these parametric values, we obtain $c_\beta^{(14)} = 0.798$ and $c_\tau^{(34)} = 1.153$. Here, the toxic $A\beta$ front propagates to the right with speed $c_\beta^{(14)}$ and fills the domain $\tilde{u}_4$ with negligible toxic τP (see Fig. 2(b)). However, we note that after filling toxic $A\beta$ in the entire domain, toxic τP starts to increase its concentration and

connects to $\tilde{v}_4$. It moves with the speed $c_\tau^{(34)}$ and fills the domain. Finally, the entire system converge to the stable equilibrium solution $(u_4, \tilde{u}_4, v_4, \tilde{v}_4)$.

Fig. 4: Front propagations of $\tilde{u}$ and $\tilde{v}$ for the system (2) at different time steps: (a) $t = 60$, (b) $t = 250$, (c) $t = 400$ and (d) $t = 425$.

6 Conclusion

We have studied a modification of the heterodimer model, which captures the conversion time from healthy to toxic proteins. For the temporal dynamics, we have carried out the linear stability analysis of all the stationary points. We have also investigated the wave speeds of the travelling wavefronts for the spatio-temporal model.

We have obtained two clinically interesting patient proteopathies for further detailed analysis: primary and secondary tauopathies. For the case of primary tauopathy, a possible invasion of τP exists independent of the invasion of $A\beta$. On the other hand, for the secondary tauopathy, the sustained presence of toxic τP requires the company of toxic $A\beta$. These conclusions are similar for both the models (heterodimer and the modified version). However, for the same parametric values, the introduction of Holling type-II functional response decreases the concentrations of toxic τP and toxic $A\beta$ compared to the original model.

References

1. Alzheimer A, Über eine eigenartige Erkrankung der Hirnrinde, *Zentralbl Nervenpsych.*, **18**: 177–179 (1907).
2. Hardy J A and Higgins G A, Alzheimer's disease: the amyloid cascade hypothesis, *Science*, **256**: 184–186 (1992).
3. Hardy J and Allsop D, Amyloid deposition as the central event in the aetiology of Alzheimer's disease, *Trends in pharmacological sciences*, **12**: 383–388 (1991).
4. Gotz J, Halliday G and Nisbet R M, Molecular pathogenesis of the tauopathies, *Annual Review of Pathology: Mechanisms of Disease*, **14**: 239–261 (2019).
5. Cho H, Choi J Y, Hwang M S, Kim Y J, Lee H M, Lee H S, et al., In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum, *Annals of neurology*, **80**: 247–258 (2016).
6. Jack C R, Bennett D A, Blennow K, Carrillo M C, Dunn B, Haeberlein S B, et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease, *Alzheimer's & Dementia*, **14**: 535–562 (2018).
7. DeVos S L, Corjuc B T, Commins C, Dujardin S, Bannon R N, Corjuc D, et al., Tau reduction in the presence of amyloid – β prevents tau pathology and neuronal death in vivo, *Brain*, **141**: 2194–2212 (2018).
8. Busche M A, Wegmann S, Dujardin S, Commins C, Schiantarelli J, Klickstein N, et al., Tau impairs neural circuits, dominating amyloid – β effects, in Alzheimer models in vivo, *Threshold*, **30**: 50 (2019).
9. Walker L C, Lynn D G and Chernoff Y O, A standard model of Alzheimer's disease?, *Prion*, **12**: 261–265 (2018).
10. Ittner L M and Gotz J, Amyloid- β and tau-a toxic pas de deux in Alzheimer's disease, *Nature Reviews Neuroscience*, **12**: 67 (2011).
11. Jack C R Jr, Knopman D S, Jagust W J, Petersen R C, Weiner M W, Aisen P S, et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, *The Lancet Neurology*, **12**: 207–216 (2013).
12. Kara E, Marks J D and Aguzzi A, Toxic protein spread in neurodegeneration: reality versus fantasy, *Trends in molecular medicine* (2018).
13. Vosoughi A, Sadigh-Eteghad S, Ghorbani M, Shahmorad S, Farhoudi M, Rafi M A and Omid Y, Mathematical Models to Shed Light on Amyloid-Beta and Tau Protein Dependent Pathologies in Alzheimer's Disease, *Neuroscience*, **424**: 45–57 (2020).
14. Thompson T B, Chaggar P, Kuhl E and Goriely A, Protein-protein interactions in neurodegenerative diseases: A conspiracy theory, *PLoS Comput Biol*, **16**: e1008267 (2020).
15. Fornari S, Schäfer A, Goriely A and Kuhl E, Prion-like spreading of Alzheimer's disease within the brain's connectome, *Interface R Society*, (2019).
16. Fornari S, Schäfer A, Kuhl E and Goriely A, Spatially-extended nucleation-aggregation-fragmentation models for the dynamics of prion-like neurodegenerative protein-spreading in the brain and its connectome, *J Theor Biol.*, **486**: 110102 (2020).
17. Jucker M and Walker L C, Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders, *Annals of Neurology*, **70**: 532–540 (2011).
18. Zheng Y Q, Zhang Y, Yau Y, Zeighami Y, Larcher K, Misisic B, et al., Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation, *bioRxiv*, **327**: 449199 (2019).

19. Insel P, Mormino E, Aisen P, Thompson W and Donahue M, Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention, *Brain Commun*, **2**: 1–11 (2020).
20. Moreno-Jimenez E, Flor-Garcia M, Adult Hippocampal Neurogenesis Is Abundant in Neurologically Healthy Subjects and Drops Sharply in Patients With Alzheimer's Disease, *Nat Med.*, **25**: 554–560 (2019).
21. Bressloff P C, Waves in neural media. *Lecture Notes on Mathematical Modelling in the Life Sciences*, (2014).
22. Matthäus F, A Comparison of Modeling Approaches for the Spread of Prion Diseases in the Brain. In: Mitkowski W, Kacprzyk J (eds) *Modelling Dynamics in Processes and Systems*, Springer, 109–117 (2009).
23. Bertsch M, Franchi B, Marcello N, Tesi M C and Tosin A, Alzheimer's disease: a mathematical model for onset and progression, *Mathematical Medicine and Biology*, dqw003 (2016).
24. Weickenmeier J, Kuhl E and Goriely A, The multiphysics of prion-like diseases: progression and atrophy, *Phys Rev Lett.*, **121**: 158101 (2018).
25. Weickenmeier J, Jucker M, Goriely A and Kuhl E, A physics-based model explains the prion-like features of neurodegeneration in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, *Journal of the Mechanics and Physics of Solids*, **124**: 264–281 (2019).
26. Dawes J H P and Souza M O, A derivation of Holling's type I, II and III functional responses in predator-prey systems, *J. Theo. Bio.*, **327**: 11–22 (2013).